Table 1.
Antifungal use Trends for April and May of 2020
| Unit | April COVID-19 PD | May COVID-19 PD | Antifungal | Mean April'19-March'20 | April'20 | April'20 vs mean | May'20 | May'20 vs mean |
|---|---|---|---|---|---|---|---|---|
| (DOT /1000 PD) | (DOT /1000 PD) | P value | (DOT /1000 PD) | P value | ||||
| MICU | 156 (28% of total PD) |
212 (30% of total PD) |
Voriconazole | 21 | 19 | .91 | 0 | .10 |
| Posaconazole | 6 | 3 | .74 | 0 | .52 | |||
| Isavuconazonium | 17 | 0 | .25 | 0 | .25 | |||
| Lip. Amphotericin B | 7 | 3 | .55 | 1 | .40 | |||
| Micafungin | 46 | 51 | .74 | 0 | .01 | |||
| PM | 280 (64% of total PD) |
304 (69% of total PD) |
Voriconazole | 1 | 2 | .57 | 0 | .61 |
| Posaconazole | 0 | 2 | .21 | 0 | .79 | |||
| Isavuconazonium | 2 | 0 | .60 | 0 | .60 | |||
| Lip. Amphotericin B | 2 | 0 | .66 | 0 | .66 | |||
| Micafungin | 8 | 2 | .48 | 0 | .38 |
DOT, days of therapy; MICU, medical intensive care unit; PD, patient days; PM, progressive medicine unit.